Brighton Jones LLC Bei Gene, Ltd. Transaction History

Brighton Jones LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$123.9 - $195.41 $337,875 - $532,883	-2,727 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$121.84 - $173.19 $36,552 - $51,957	-300 Reduced 9.91%	2,727 $336,000
Q4 2019 Feb 07, 2020	SELL	$115.78 - $208.34 $31,607 - $56,876	-273 Reduced 8.27%	3,027 $502,000
Q3 2019 Oct 28, 2019	BUY	$120.61 - $148.29 $398,013 - $489,357	3,300 New	3,300 $404,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Brighton Jones LLC, based on Form 13F filings with the SEC.

Stay updated on Brighton Jones LLC with notifications on news.